Elected by a body of fellow immunotherapy researchers from across the globe, Roswell Park Comprehensive Cancer Center Deputy Director Kunle Odunsi, MD, PhD, FRCOG, FACOG, has been named At-Large Director of the Society for Immunotherapy of Cancer (SITC) Board of Directors. Dr. Odunsi will begin his 3-year term in January 2021.
Kunle Odunsi, MD, PhD, FRCOG, FACOG
Founded in 1984, SITC seeks to make cancer immunotherapy a standard of care, striving to improve patient care outcomes by advancing the science and application behind this treatment.
A Vision of Hope
Dr. Odunsi, who is also the Robert, Anne & Lew Wallace Endowed Chair in Cancer Immunotherapy, Executive Director of the Center for Immunotherapy, and M. Steven Piver Endowed Professor and Chair of the Department of Gynecologic Oncology at Roswell Park, highlighted his deep passion for advancing immunotherapy research in his platform statement. “My vision is that the SITC becomes a major voice for communicating and advocating for cancer immunology research and treatment and for the resources that would further propel the immunology revolution to its ultimate destination of changing cancer from a terrifying disease to that of a curable disease,” he wrote.
On staff at Roswell Park since 2001, Dr. Odunsi has authored and coauthored more than 350 journal publications and book chapters. A Fellow of both the Royal College of Obstetricians and Gynaecologists in the United Kingdom and the American College of Obstetricians and Gynecologists, he holds lifetime membership in the National Academy of Medicine, one of the highest honors in medicine.
